|
|
|
|
||
Re: ESMO LBA Another poster: https://cslide.ctimeetingtech.com/esmo2018/attendee/confcal/show/session/147 1050PD - Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)Presentation Number
1050PD
|
return to message board, top of board |